Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Bicalutamide; Gonadotropin releasing hormone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms FORMULA-509
- 31 Aug 2018 Biomarkers information updated
- 25 Jan 2018 Status changed from not yet recruiting to recruiting.
- 01 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.